Clinical Efficacy of Dofetilide for the Treatment of Atrial Tachyarrhythmias in Adults with Congenital Heart Disease. (15th August 2013)

• Record Type: Journal Article
• Authors: Banchs, Javier E.; Baquero, Giselle A.; Nickolaus, Michelle J.; Wolbrette, Deborah L.; Kelleman, John J.; Samii, Soraya; Grando‐Ting, Jennifer; Penny‐Peterson, Erica; Davidson, William R.; Young, Sallie K.; Naccarelli, Gerald V.; Gonzalez, Mario D.
• Is Part Of: Congenital heart disease. Volume 9:Number 3(2014)
• Page Start: 221
• Page End: 227
• Publication Date: 2013-08-15
• Subjects: Congenital heart disease -- Periodicals; 616.1204305
• DOI: 10.1111/chd.12129
• Languages: English
• ISSNs: 1747-079X

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="chd12129-sec-0001" sec-type="section"> <title>Background</title> <p>Atrial tachyarrhythmias (AT) including atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia represent a clinical challenge in the adult with congenital heart disease (CHD). Dofetilide (D) is a rapidly activating delayed rectifier potassium channel (IKr) blocker effective in pharmacological conversion and maintenance of normal sinus rhythm in patients with AF and AFL. There is limited knowledge regarding the role of D in adults with CHD.</p> </sec> <sec id="chd12129-sec-0002" sec-type="section"> <title>Methods</title> <p>Safety and efficacy of D was evaluated in a consecutive group of thirteen adult patients (age 40 ± 11; six women) with CHD and refractory AT.</p> </sec> <sec id="chd12129-sec-0003" sec-type="section"> <title>Results</title> <p>Ten patients had persistent (four AFL, one AF, and five atrial tachycardia) and three paroxysmal (one AF and two atrial tachycardia) AT. All patients were symptomatic during tachycardia, 12 patients had previously failed 2 ± 1 antiarrhythmic drugs. Mean systemic ventricular ejection fraction was 55 ± 9%; baseline QRS complex duration was 129 ± 45 ms (>120 ms in six patients). Patients were followed on D for 33 ± 39 months (median 16). Among 10 patients with persistent AT, seven patients (70%) pharmacologically converted to sinus rhythm on D and three patients (30%) required direct current cardioversion. Two patients (15.4%) experienced complete arrhythmia suppression, and seven (53.8%) experienced significant clinical improvement with sporadic recurrences; average time to recurrence was 5.5 ± 3.5 months. One patient developed torsade de pointes during loading, and the drug was discontinued. D was discontinued in five (38.5%) other patients due to recurrence of AT (n = 4) and renal failure (n = 1). Corrected QT interval (QTc) increased from 452 ± 61 to 480 ± 49 ms (<italic>P</italic> = .04) and corrected JT interval (JTc) from 323 ± 39 to 341 ± 33 ms (<italic>P</italic> = .09).</p> </sec> <sec id="chd12129-sec-0004" sec-type="section"> <title>Conclusions</title> <p>D should be considered a pharmacologic alternative when adult patients with CHD develop AT. D does not depress conduction, sinus node, or ventricular function but needs close monitoring for potential ventricular pro‐arrhythmia.</p> </sec> </abstract>